BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.
| Revenue (TTM) | $2.00M |
| Gross Profit (TTM) | $-32.90M |
| EBITDA | $-49.59M |
| Operating Margin | -2495.00% |
| Return on Equity | -814.00% |
| Return on Assets | -133.10% |
| Revenue/Share (TTM) | $1.59 |
| Book Value | $-22.48 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 3.38 |
| EV/Revenue | 5.54 |
| EV/EBITDA | 0.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 31.60% |
| Shares Outstanding | $1.66M |
| Float | $1.37M |
| % Insiders | 5.46% |
| % Institutions | 22.53% |
Volatility is currently expanding